Clinical Trial Results:
A Phase III, Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Cell Disease who have had ≥ 2 Acute Sickle-Related Painful Crises within the Preceding 12 Months.
Summary
|
|
EudraCT number |
2004-004617-42 |
Trial protocol |
GB |
Global completion date |
01 Jun 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Dec 2016
|
First version publication date |
29 Dec 2016
|
Other versions |
|
Summary report(s) |
ICA-17043-10 Public Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.